Published in Oncotarget on June 21, 2016
Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget (2017) 0.76
Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer. J Biol Chem (2016) 0.76
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Oncotarget (2016) 0.75
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Target Oncol (2017) 0.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 2.12
Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med (2015) 2.01
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol (2014) 1.79
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol (2016) 1.58
Prostate cancer. Lancet (2015) 1.58
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol (2016) 1.09
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer (2015) 1.04
Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol (2014) 0.92
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep (2013) 0.88
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate (2014) 0.87
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncol (2015) 0.80
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE. Eur J Nucl Med Mol Imaging (2016) 1.06
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2014) 1.00
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget (2016) 0.93
Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS One (2015) 0.84
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget (2016) 0.84
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clin Lung Cancer (2015) 0.82
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. Oncotarget (2016) 0.82
Improved stool DNA integrity method for early colorectal cancer diagnosis. Cancer Epidemiol Biomarkers Prev (2014) 0.81
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget (2016) 0.80
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. J Neurooncol (2016) 0.78
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. Eur J Cancer (2015) 0.78
Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. Int J Public Health (2017) 0.78
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging (2015) 0.77
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. Clin Genitourin Cancer (2016) 0.76
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. Oncol Lett (2015) 0.76
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget (2017) 0.76
Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. Oncotarget (2017) 0.75
Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer. Oncotarget (2016) 0.75
miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther (2016) 0.75
Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther (2016) 0.75
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. Cancer Chemother Pharmacol (2017) 0.75
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Sci Rep (2016) 0.75
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer. Oncotarget (2017) 0.75
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report. BMC Cancer (2016) 0.75
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. Eur J Nucl Med Mol Imaging (2017) 0.75
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE. Eur J Nucl Med Mol Imaging (2016) 0.75
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urol Oncol (2017) 0.75
Reduction of (68)Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging (2017) 0.75
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clin Cancer Res (2016) 0.75
Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience. Technol Cancer Res Treat (2014) 0.75
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. Breast Cancer Res Treat (2016) 0.75
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. Oncologist (2017) 0.75
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep (2017) 0.75